ReviewFrontiers in immunology2025
Solute carrier protein family: physiological functions, disease associations, and therapeutic potential in immune-related disorders.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Solute Carrier Protein Family (SLC) is responsible for the uptake and transport of a variety of substances across the cell membrane. It plays a central role in maintaining the stability of the intracellular environment through participation in metabolic processes and the transport of drugs and toxins. The highly tissue-specific expression of SLC proteins endows them with potential applications in disease treatment and drug development. Transplant immune reactions are a major challenge in the field of organ transplantation, as graft rejection is a key factor determining the success of transplantation and long-term organ survival. SLC proteins are increasingly drawing attention for their roles in modulating immune responses, influencing transplant immune tolerance, and controlling graft rejection. By regulating the metabolism and function of immune cells, SLC proteins affect the formation and tolerance of transplant immune responses. Among them, 7 SLC proteins are "validated targets" with approved or phase III drugs, 9 are "candidate targets" in active clinical trials, and 14 remain "potential targets" supported by genetic and pre-clinical evidence. This article elucidates the functions of SLC proteins in transplant immunology, inflammation and autoimmune diseases, tumor immunology, metabolic diseases, and neurological diseases, as well as the new targets and strategies for treating these diseases that SLC proteins provide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.